“We look forward to sharing topline data from the Phase 1 portion of the Phase 1/2a trial of IMM-1-104 this month. IMM-1-104’s unique deep cyclic inhibition mechanism was designed for broad universal-RAS activity and a differentiated safety profile. We believe this update will provide important insights on the primary and secondary endpoints of the Phase 1 portion of the trial, and is a key milestone that builds on the substantial progress made in 2023,” said Ben Zeskind, Chief Executive Officer, Immuneering. “Importantly, 2024 is shaping up to be even more exciting, as we look forward to data readouts from multiple arms of the expanded Phase 2a portion of our Phase 1/2a trial of IMM-1-104, and launch our Phase 1/2a trial of IMM-6-415.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IMRX:
- Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
- Immuneering receives FDA Fast Track designation for IMM-1-104
- Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer
- Immuneering Announces Participation in February Investor Conferences
